Obstructive sleep apnea (OSA) is the most common clinically significant breathing abnormality during sleep. It is highly prevalent among patients with atrial fibrillation (AF), and it promotes arrhythmogenesis and impairs treatment efficacy.
A trial fibrillation (AF) is the most common sustained arrhythmia worldwide, affecting 33.5 million people globally. 1 Across the developed world, AF increasingly contributes to a rising tide of hospitalization, morbidity, and mortality.
2,3 The prevalence of sleep apnea, particularly obstructive sleep apnea (OSA), is 21% to 74% in patients with AF.
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Obstructive sleep apnea is an independent predictor of stroke in patients with AF 15 and reduces the efficacy of catheter-based [16] [17] [18] [19] [20] [21] and pharmacological 22 antiarrhythmic therapy. Several studies suggest that treatment of OSA by continuous positive airway pressure (CPAP) may lower the rate of AF recurrence after electrical cardioversion (Table 1 4 -8,20-22,41 ), 5 and it improves catheter ablation success rates in patients with AF. [23] [24] [25] [26] [27] [28] With accumulating evidence, international professional societies recommend the examination of patients for clinical symptoms and signs of OSA, as well as CPAP treatment to maintain sinus rhythm. 3, 29 This review provides an update on the current understanding of the pathophysiology of OSA and the associated development of a unique dynamic arrhythmogenic substrate in OSA for AF. We highlight diagnostic and therapeutic considerations in patients with AF who also have OSA, as well as experimental data pointing to possible mechanisms for AF and the antiarrhythmic effects of OSA treatment in patients with AF and comorbid OSA. Finally, we emphasize the need for randomized clinical trials to more definitively establish the role of OSA and its treatment in predisposing to incident and recurrent AF.
Pathophysiology
During sleep, respiration is more vulnerable to disruption from upper airway obstruction, dysregulation of respiratory control, and hypoventilation compared with the awake state. 30 The most common clinically significant breathing abnormality during sleep is OSA. 30 This disorder is characterized by repetitive partial collapse of the airway (obstructive hypopnea) or complete collapse of the upper airway (obstructive apnea) during sleep, both of which engender ongoing and typically increasing inspiratory efforts.
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Patients with central sleep apnea (CSA) associated with central dysregulation of respiratory control represent just a fraction of the large group of patients with sleep apnea and accompanying cardiovascular diseases. 30 Central sleep apnea is characterized by periodic episodes of hyperventilation and hypoventilation resulting in intermittent changes in carbon dioxide and tidal volume. Dysregulation of respiratory control in CSA is associated with increased sensitivity of peripheral and central chemoreceptors, pulmonary congestion, and prolonged circulation time.
In OSA, episodes of hypopnea typically occur far more frequently than episodes of apnea, and obstructive as well as central respiratory events may both occur during the same night in a single patient. However, individual patients generally show either predominant OSA or predominant CSA. Patients with OSA sometimes convert to CSA once established on CPAP treatment. This likely reflects a central component of unstable ventilatory control underpinning their OSA, which is then unmasked by CPAP. This phenomenon is more prevalent in patients with heart failure and pulmonary edema.
In addition to high-frequency intermittent deoxygenation and reoxygenation, negative intrathoracic pressure swings during inspiration against an occluded upper airway in OSA cause myocardial stretch and changes in transmural pressure gradients, particularly affecting the thin-walled atria. 30, 31 Additionally, obstructive respiratory events increase venous return, augmenting right atrial and right ventricular preload, 32,33 while OSA-induced hypoxic pulmonary vasoconstriction increases afterload to the right side of the heart. Consequent right ventricular and right atrial distension, and leftward septal displacement during diastole impairs left ventricular filling and further increases left atrial volume loading. 30, 31 The hemodynamic responses to hypopnea or central sleep apnea may be less pronounced compared with those occurring in obstructive apnea because they are usually associated with less severe hypoxemia and intrathoracic pressure changes (Box).
Atrial Remodeling in Long-term OSA
Intermittent hypoxia in rats, induced by repetitive interruptions of ventilation during daily intubation, have shown atrial conduction abnormalities associated with connexin dysregulation and increased atrial fibrosis after 4 weeks of simulated sleep apnea. 34 Correspondingly, patients with long-term OSA manifest marked atrial structural changes and conduction abnormalities in the atria without experiencing any changes in atrial refractoriness that form a substrate for AF vulnerability.
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Repetitive obstructive respiratory events may cause structural remodeling and myocardial damage through repetitive mechanical atrial distension, atrial wall stretch, and frequent episodes of hemoglobin desaturation and resaturation. Intermittent deoxygenation and reoxygenation of the type that occurs in sleep apnea differs from the sustained hypoxemia occurring at high altitudes and with chronic lung disease. Chronic hypoxemia promotes remodeling by modulating the expression of hypoxia-inducible factor 1 and 2. 36 The cyclical deoxygenation and reoxygenation associated with sleep apnea is comparable with ischemia and reperfusion injury, increasing production of reactive oxygen species, vascular inflammation, and blood pressure. 37 All of these may cause myocardial damage. 47 the transition from hypercapnia back to normal blood-gas levels, rather than longer hypoxic or hypercapnic episodes, was characterized by increased atrial vulnerability because of a differential recovery of atrial refractoriness and atrial conduction properties. 47 Besides these apnea-associated changes in conduction and atrial refractoriness that contribute to the substrate for AF, acute apneas may also increase trigger formation. The pronounced sympathetic activation that occurs toward the end of an obstructive episode is accompanied by vagally mediated bradycardia because of activation of the diving reflex. 48 This sympathovagal activation likely induces acute electrophysiological arrhythmogenic changes and an increased frequency of premature atrial contractions with the potential to initiate AF in a vulnerable substrate (Box). 43, 44 Animal models simplify the complex pathophysiology of OSA. Factors such as nocturnal hypoxemic burden and nightto-night variability may be not considered sufficiently and should be evaluated in future translational research projects.
Obstructive Sleep Apnea and a Unique Complex and Dynamic Substrate for Atrial Fibrillation
In long-term OSA, atrial stretch, neurohumoral activation, and chronic concomitant conditions, such as hypertension, metabolic syndrome, and obesity, create a progressive structural atrial substrate remodeling in patients. This progressive atrial structural remodeling, along with transient apnea-associated electrophysiological changes, contributes to the reentry substrate for AF and creates a complex and dynamic arrhythmogenic substrate in the atrium during sleep. Atrial fibrillation risk increases cumulatively with the progressive atrial structural remodeling and apnea-associated arrhyth- While quantification of daytime sleepiness helps to assess the neurobehavioral impact of sleep apnea and the need for treatment, the goal of sleep apnea management in AF is to ameliorate its adverse effects on cardiac structure and function. Several diagnostic sleepstudy options are available, including full polysomnography; simpler cardiorespiratory monitoring with a more restricted number of parameters measured (usually oxygen saturation, respiratory effort and airflow) without electroencephalographic assessment of sleep (polygraphy); overnight oxymetry; or special analysis algorithms of ambulatory electrocardiographic testing or implantable device recordings ( Table 2) . 3 Sleep apnea screening can be conducted in a sleep laboratory or at home. The diagnosis and treatment of sleep apnea in patients with AF requires a close interdisciplinary collaboration between the electrophysiologist or cardiologist and sleep specialists, possibly within an integrated care model. Polygraphy may be a suitable method to ensure patient access to screening for OSA in the standard clinical In accordance with current recommendations, 49 the severity of sleep apnea in patients with AF has been determined in most clinical studies with the Apnea Hypopnea Index (AHI). The AHI was initially used in pulmonology and sleep medicine to quantify respiratory disturbances. It is defined as the number of apneas and hypopneas per hour of sleep (polysomnography) or per hour of recording time (polygraphy), which may only be a crude estimate of sleep apnea severity. In this index, apneas are defined by a drop greater than 90% from the peak signal excursion of the pre-event baseline of the thermistor signal for longer than 10 seconds without a requirement for oxygen desaturation. Hypopneas are assessed based on a peak of the thermistor signal excursion drop greater than 30% for at least 10 seconds accompanied by oxygen desaturation of 3% to 4% or more from pre-event baseline or by an arousal from sleep.
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The AHI does not specifically encapsulate the absolute degree and duration of oxygen desaturation, and cannot differentiate between patients with short episodes of apnea or hypopnea and slight oxygen desaturation from those with the same or similar number but much longer and more marked oxygen desaturation. Additionally, the fact that hypopneas are not scored uniformly and that the definition of an apnea does not require a concomitant desaturation can result in a significant divergence between the AHI and the oxygen desaturation index defined as the number of desaturations per hour of sleep (polysomnography) or per hour of recording time (polygraphy). Thus, the AHI may not be the best sleep apnea metric to predict the progression of cardiac remodeling and cardiovascular events triggered by hypoxia. In a cohort study of 3542 adults, all of whom were free of history of AF, Gami et al 53 reported that, in patients younger than 65 years, obesity and the magnitude of nocturnal oxygen desaturation were independent predictors of newonset AF, not the AHI. Interestingly, a similar link was found for patients with heart failure, where previous studies had suggested that the nocturnal hypoxemic burden was a much stronger independent predictor of all-cause mortality than the AHI was.
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Prevalence of Sleep Apnea in Patients With AF
The threshold AHI score used for the diagnosis of sleep apnea in the various studies investigating the prevalence and incidence of AF ranges between 5 and 15 episodes of apnea or hypopnea per hour. A revision of American Academy of Sleep Medicine scoring rules in 2012 49 led to a less strict definition of hypopnea, more people being diagnosed with sleep apnea, and larger numbers considered to have severe sleep apnea. These and other limiting factors make a direct comparison of the different studies difficult. Partly because of the increasing sensitivity of sleep-study recording techniques and scoring criteria, the prevalence of sleep apnea has ranged widely (between 3% and 49%) in different population-based samples. [4] [5] [6] [7] [8] Notwithstanding these methodological limitations, the estimated prevalence of sleep apnea in patients with AF has been found to be much higher (21% to 74%) than in control participants without AF (Table 1) . [4] [5] [6] [7] [8] 41 Conversely, the prevalence of nocturnal AF in patients with sleep apnea has been estimated at 3% to 5%, 39 which is somewhat higher than the prevalence in control patients or the general population (0.4% to 1%). 40 The Sleep Heart Health study com- without OSA, patients with OSA who were not treated with CPAP had more nonpulmonary vein antrum triggers and posterior wall firing, which is possibly a reflection of atrial electrical and structural remodeling. 12 Not using CPAP, in addition to having nonpulmonary vein triggers, predicts PVI failure (hazard ratio, 8.81). 12 Metaanalyses of observational studies with a total of approximately 1000 patients show that patients with OSA have a 31% greater AF recurrence rate after PVI (Table 1) .
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Treatment of Sleep Apnea in Patients With AF
CPAP treatment
There have been no randomized studies on the effect of CPAP on AF recurrence. Nonrandomized observational studies suggest that CPAP can help to maintain sinus rhythm in patients with AF who have OSA (Table 3) . [23] [24] [25] [26] [27] [28] Among 39 patients with OSA undergoing cardioversion for AF, patients receiving CPAP treatment were less likely to have AF recurrences at 12 months compared with an untreated group (no CPAP, 82%; vs CPAP, 42%; P =.01;vsnoOSA,53%; P = .009). 5 In patients with OSA and AF undergoing PVI (n = 62), CPAP treatment was associated with a higher AF-free survival rate at 12 months after the procedure (71.9% vs 36.7% without CPAP), and this rate of survival was almost similar to patients without OSA. 
Conclusions
Sleep apnea creates a unique complex and dynamic substrate for AF. As most patients with AF and severe OSA do not report daytime sleepiness, sleep study evaluation may be reasonable in symptomatic patients with AF considered for a rhythm control strategy. The prevalence of sleep apnea is 3% to 49% in population-based samples and 21% to 74% in patients with AF. The presence of OSA reduces the efficacy of catheter-based and pharmacological antiarrhythmic treatment. Observational data suggest that treatment of OSA by CPAP helps to maintain sinus rhythm after electrical cardioversion and to improve catheter ablation success rates in patients with AF. However, before further recommendations can be made, randomized prospective clinical trials are required to confirm the association between OSA and AF, to clarify the benefits of treatment of OSA, to clarify the need and cost-effectiveness of routine OSA screening and treatment, and to firmly establish the role of OSA treatment in AF management guidelines. The optimal metric to determine sleep apnea severity and guide OSA therapy for patients with AF also needs further study.
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